A combination of radiotherapy, hyperthermia, and immunotherapy inhibits pancreatic tumor growth and prolongs the survival of mice
Author
Mahmood, J.Alexander, A.A.
Samanta, S.
Kamlapurkar, S.
Singh, P.
Saeed, A.
Carrier, F.
Cao, X.
Vujaskovic, Z.
Date
2020Journal
CancersPublisher
MDPI AGType
Article
Metadata
Show full item recordAbstract
Background: Pancreatic cancer (PC) is the fourth-most-deadly cancer in the United States with a 5-year survival rate of only 8%. Unfortunately, only 10-20% of PC patients are candidates for surgery, with the vast majority of patients with locally-advanced disease undergoing chemotherapy and/or radiation therapy (RT). Current treatments are clearly inadequate and novel strategies are crucially required. We investigated a novel tripartite treatment (combination of tumor targeted hyperthermia (HT), radiation therapy (RT), and immunotherapy (IT)) to alter immunosuppressive PC-tumor microenvironment (TME). (2). Methods: In a syngeneic PC murine tumor model, HT was delivered before tumor-targeted RT, by a small animal radiation research platform (SARRP) followed by intraperitoneal injections of cytotoxic T-cell agonist antibody against OX40 (also known as CD134 or Tumor necrosis factor receptor superfamily member 4; TNFRSF4) that can promote T-effector cell activation and inhibit T-regulatory (T-reg) function. (3). Results: Tripartite treatment demonstrated significant inhibition of tumor growth (p < 0.01) up to 45 days post-treatment with an increased survival rate compared to any monotherapy. Flow cytometric analysis showed a significant increase (p < 0.01) in cytotoxic CD8 and CD4+ T-cells in the TME of the tripartite treatment groups. There was no tripartite-treatment-related toxicity observed in mice. (4). Conclusions: Tripartite treatment could be a novel therapeutic option for PC patients. Copyright 2020 by the authors.Sponsors
William and Ella Owens Medical Research FoundationIdentifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084007142&doi=10.3390%2fcancers12041015&partnerID=40&md5=d27f076290292e2206b073b425d5e51e; http://hdl.handle.net/10713/12713ae974a485f413a2113503eed53cd6c53
10.3390/cancers12041015